Fox Run Management L.L.C. Purchases 16,961 Shares of Kodiak Sciences Inc. $KOD

Fox Run Management L.L.C. raised its holdings in shares of Kodiak Sciences Inc. (NASDAQ:KOD) by 136.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 29,419 shares of the company’s stock after purchasing an additional 16,961 shares during the quarter. Fox Run Management L.L.C. owned 0.06% of Kodiak Sciences worth $823,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also bought and sold shares of the company. EverSource Wealth Advisors LLC lifted its position in Kodiak Sciences by 1,221.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 991 shares of the company’s stock valued at $28,000 after purchasing an additional 916 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in Kodiak Sciences during the 4th quarter valued at $29,000. Headlands Technologies LLC raised its holdings in Kodiak Sciences by 256.4% during the 2nd quarter. Headlands Technologies LLC now owns 8,083 shares of the company’s stock valued at $30,000 after buying an additional 5,815 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Kodiak Sciences during the 4th quarter valued at $72,000. Finally, Strs Ohio purchased a new position in shares of Kodiak Sciences during the fourth quarter valued at approximately $87,000. Institutional investors own 89.06% of the company’s stock.

Kodiak Sciences Stock Up 1.1%

KOD opened at $31.41 on Thursday. The firm’s 50-day moving average price is $39.55 and its 200-day moving average price is $30.47. Kodiak Sciences Inc. has a 52-week low of $3.43 and a 52-week high of $47.84. The company has a market cap of $1.97 billion, a P/E ratio of -7.53 and a beta of 2.21.

Kodiak Sciences (NASDAQ:KOD) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.94) EPS for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.01). On average, research analysts anticipate that Kodiak Sciences Inc. will post -3.89 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Wall Street Zen upgraded Kodiak Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Chardan Capital raised Kodiak Sciences from a “neutral” rating to a “buy” rating and upped their price objective for the company from $14.00 to $61.00 in a research report on Monday, May 11th. UBS Group upped their price objective on Kodiak Sciences from $50.00 to $80.00 and gave the company a “buy” rating in a research report on Friday, March 27th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $58.00 price objective (up from $38.00) on shares of Kodiak Sciences in a research report on Friday, March 27th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $42.14.

Kodiak Sciences Profile

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.